Kymera Therapeutics (KYMR) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to -$0.94.
- Kymera Therapeutics' EPS (Weighted Average and Diluted) fell 1463.41% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6, marking a year-over-year decrease of 5384.62%. This contributed to the annual value of -$2.98 for FY2024, which is 1837.4% down from last year.
- As of Q3 2025, Kymera Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.94, which was down 1463.41% from -$0.95 recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.25 during Q4 2023, and its lowest value of -$0.95 during Q2 2025.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.7 (2022), whereas its average is -$0.72.
- As far as peak fluctuations go, Kymera Therapeutics' EPS (Weighted Average and Diluted) soared by 5762.71% in 2023, and later tumbled by 27712.28% in 2024.
- Kymera Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.67 in 2021, then rose by 11.94% to -$0.59 in 2022, then soared by 57.63% to -$0.25 in 2023, then crashed by 277.12% to -$0.94 in 2024, then increased by 0.3% to -$0.94 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.94 for Q3 2025, versus -$0.95 for Q2 2025 and -$0.82 for Q1 2025.